. 2014 Oct 15;9(10):e109430. doi: 10.1371/journal.pone.0109430

Table 3. Focused miRNA panel – miRNAs significantly associated with overall survival.

	Screening CAPEOXBEV cohort			Validation CAPEOXBEV cohort			Combined CAPEOXBEV cohort			Control CAPEOX cohort			Interaction^a
	n = 155			n = 121			n = 276			n = 127			all	distal	proximal
miRNA	HR^b	95% CI	P	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P	P	P	P
Raw expression values
miR-15a-5p	0.80	0.65–0.99	0.04	0.87	0.66–1.16	0.34	0.81	0.69–0.97	0.02	1.05	0.83–1.34	0.68	0.31	0.41	0.74
miR-196b-5p	0.83	0.69–1.01	0.06	0.66	0.50–0.87	0.003	0.77	0.66–0.90	0.0008	0.78	0.62–0.98	0.04	0.20	0.06	0.23
miR-204-5p	0.76	0.64–0.91	0.003	0.88	0.66–1.18	0.38	0.77	0.64–0.93	0.005	1.02	0.81–1.28	0.87	0.94	0.80	0.54
miR-338-3p	0.81	0.65–1.00	0.045	0.93	0.70–1.24	0.63	0.85	0.72–1.01	0.07	1.01	0.80–1.27	0.92	0.52	0.40	0.68
miR-545-3p	0.85	0.74–0.98	0.03	0.95	0.80–1.12	0.53	0.90	0.81–1.01	0.06	1.06	0.95–1.19	0.30	0.39	0.39	0.45
miR-552	0.77	0.61–0.96	0.02	0.93	0.68–1.27	0.63	0.77	0.63–0.95	0.01	1.02	0.80–1.31	0.85	0.44	0.29	0.76
miR-592	0.69	0.69–0.92	0.01	0.76	0.60–0.95	0.01	0.73	0.62–0.86	0.0001	0.76	0.55–1.05	0.10	0.31	0.33	0.85
miR-664-3p	0.64	0.48–0.86	0.003	0.60	0.44–0.82	0.002	0.61	0.49–0.75	<0.0001	0.85	0.61–1.17	0.31	0.02	0.03	0.50
Mean-normalized expression values
miR-1	1.01	0.77–1.32	0.96	1.19	0.84–1.69	0.32	1.08	0.87–1.32	0.49	1.36	1.02–1.82	0.04	0.98	0.82	0.75
miR-155-5p	1.31	1.03–1.67	0.03	1.21	0.91–1.61	0.19	1.23	1.03–1.47	0.03	0.96	0.75–1.23	0.76	0.38	0.70	0.30
miR-185-5p	1.49	1.18–1.88	0.0008	1.23	0.89–1.72	0.21	1.34	1.12–1.60	0.001	0.91	0.70–1.18	0.46	0.09	0.23	0.57
miR-196b-5p	0.89	0.67–1.18	0.43	0.70	0.51–0.96	0.03	0.79	0.64–0.97	0.03	0.73	0.58–0.93	0.01	0.99	0.43	0.09
miR-204-5p	0.75	0.61–0.93	0.009	0.95	0.70–1.28	0.71	0.85	0.72–1.01	0.06	1.01	0.85–1.21	0.89	0.43	0.61	0.40
miR-455-5p	1.19	0.95–1.49	0.14	1.27	1.03–1.56	0.03	1.24	1.06–1.45	0.007	0.99	0.85–1.15	0.91	0.02	0.19	0.38
miR-592	0.77	0.59–1.00	0.05	0.76	0.63–0.93	0.007	0.77	0.66–0.89	0.0004	0.71	0.53–0.96	0.03	0.52	0.21	0.35
miR-664-3p	0.66	0.49–0.91	0.01	0.55	0.39–0.79	0.001	0.60	0.48–0.76	<0.0001	0.81	0.59–1.11	0.18	0.02	0.02	0.45

Interaction was tested for all patients and for patients with distal (sigmoid to rectum) and proximal (cecum to descending colon) primary tumor location separately.

Hazard ratio is per inter-quartile range expression increase and is adjusted for age, sex, number of metastatic sites, prior adjuvant treatment and primary tumor location.

Abbreviations: HR, hazard ratio; CI, confidence interval.